STOCK TITAN
  1. Home
  2. News
  3. CTLT

Catalent Inc. - CTLT STOCK NEWS

Welcome to our dedicated news page for Catalent (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Catalent's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Catalent's position in the market.

News
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
Rhea-AI Summary
Catalent, Inc. (CTLT) commits to reducing greenhouse gas emissions by 42% by 2030 from its 2022 baseline, with a focus on supplier emissions. The company implements ISO-certified environmental management systems at 24 locations, emphasizing environmental sustainability, diversity, and community support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
News
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) reported a Q2'24 net revenue of $1.03 billion, a 10% decrease from Q2'23, excluding COVID-related revenue, net revenue increased by 8%. The net loss was $(204) million compared to $81 million of net income in Q2'23. Adjusted EBITDA was $124 million, a 56% decrease from Q2'23. Catalent raised $600 million in term loans, with total available liquidity of ~$1.3 billion. Novo Holdings will acquire Catalent in an all-cash transaction valued at $16.5 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
earnings
-
News
Novo Holdings to Acquire Catalent
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) has entered into a merger agreement with Novo Holdings, under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion. Stockholders will receive $63.50 per share in cash, representing a 47.5% premium to the 60-day Volume-Weighted Average Price as of February 2, 2024. Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk shortly after the closing of the merger. The merger is expected to close towards the end of calendar year 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.74%
Tags
acquisition
News
Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast
Rhea-AI Summary
Catalent, Inc. (CTLT) will release financial results for the second quarter of fiscal year 2024 on February 9, 2024. The webcast to discuss the results will be accessible through Catalent’s website. The Company’s management will host the webcast at 8:15 a.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
earnings
-
News
Catalent Commits to Reducing Greenhouse Gas Emissions by 2030
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) has announced its targets to reduce greenhouse gas emissions by 42% by 2030, validated by the Science Based Targets initiative (SBTi). The company also committed to engaging with its suppliers to align their emissions reduction goals with science-based targets. Catalent has achieved its initial carbon reduction goal ahead of time through energy reduction projects and transitioning its sites to renewable electricity. The company has reinforced its roadmap to reduce greenhouse gas emissions and conducted its first Scope 3 inventory, showing that more than 80% of its emissions are generated by its value chain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
News
Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) to participate at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences
News
Catalent Announces Closing of Incremental Term Loans
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) announced a $600 million incremental term loan issuance to repay outstanding borrowings and strengthen its capital structure, increasing total liquidity to approximately $1.3 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
none
-
News
Catalent Regains Compliance with NYSE Continued Listing Standards
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) has regained compliance with the NYSE continued listing standards after filing its Annual Report on Form 10-K for the year ended June 30, 2023 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. This has cured Catalent of the previously disclosed non-compliance with exchange listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News
Catalent, Inc. Reports Preliminary First Quarter Fiscal 2024 Results and Reaffirms Full-Year Fiscal 2024 Guidance
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) announced Q1'24 net revenue of $982 million, a 4% decrease from Q1'23. The net loss was $(715) million, including non-cash goodwill impairment charges of $700 million. Adjusted EBITDA was $115 million, a 38% decrease from Q1'23. The company reaffirmed FY'24 financial guidance of $4.3 billion to $4.5 billion in net revenue and $680 million to $760 million in Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.34%
Tags
earnings
News
Catalent, Inc. Announces First Quarter Fiscal Year 2024 Earnings Conference Webcast
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) will release preliminary financial results for Q1 of fiscal year 2024 on November 15, 2023. A webcast to discuss the results will be hosted at 8:15 a.m. ET on the same day. Interested parties can access the webcast and supplemental slide presentation on Catalent's website. The webcast replay and slides will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.85%
Tags
earnings
Stock CTLT logo
Catalent Inc.

NYSE:CTLT

CTLT Rankings

#797 Ranked by Market Cap
#4338 Ranked by Stock Gains
N/A Ranked by Dividends

CTLT Stock Data

10.18B
179.72M
0.49%
111.38%
4.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Somerset

About CTLT

catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p